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Abstract 
Radiotherapy (RT) still represents a mainstay of treatment in clinical oncology. Traditionally, the effectiveness of 
radiotherapy has been attributed to the killing potential of ionizing radiation (IR) over malignant cells, however, it 
has become clear that therapeutic efficacy of RT also involves activation of innate and adaptive anti‑tumor immune 
responses. Therapeutic irradiation of the tumor microenvironment (TME) provokes profound cellular and biological 
reconfigurations which ultimately may influence immune recognition. As one of the major constituents of the TME, 
cancer‑associated fibroblasts (CAFs) play central roles in cancer development at all stages and are recognized con‑
tributors of tumor immune evasion. While some studies argue that RT affects CAFs negatively through growth arrest 
and impaired motility, others claim that exposure of fibroblasts to RT promotes their conversion into a more activated 
phenotype. Nevertheless, despite the well‑described immunoregulatory functions assigned to CAFs, little is known 
about the interplay between CAFs and immune cells in the context of RT. In this review, we go over current literature 
on the effects of radiation on CAFs and the influence that CAFs have on radiotherapy outcomes, and we summarize 
present knowledge on the transformed cellular crosstalk between CAFs and immune cells after radiation.
Keywords: Cancer‑associated fibroblasts, CAFs, Immunosuppression, Ionizing radiation, Radiotherapy, Tumor 
microenvironment, TME
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Introduction
After more than 100 years at service, radiotherapy (RT) 
still represents a predominant and cost-effective treat-
ment modality in modern cancer care [1], securing 
around 40% of cancer cures when used alone or in com-
binatory strategies [2]. Recently, immense technological 
advances, in particular novel concepts like stereotactic 
body radiotherapy (SBRT) [3], has triggered a paradigm 
shift in treatment strategies and associated patient out-
comes, where high-precision dose-delivery and minimal 
exposure to normal tissue is allowing intensified treat-
ment regimens in curative settings [4, 5].
The long-standing success of clinical radiotherapy 
is traditionally attributed to its capacity for inducing 
apoptosis in neoplastic cells. However, within the care-
fully delineated target-volume, the complete collec-
tion of cellular and acellular components present in the 
tumor microenvironment (TME) is unavoidably affected 
by the potent beams of ionizing radiation (IR) [6, 7]. 
Hence, radiotherapy is naturally also triggering paral-
lel responses such as vascular responses, altered immu-
nity, antigen release, inflammatory processes, transient 
hypoxia and fibrosis, to name a few [8, 9].
From the immunological point of view, research efforts 
over the last decade have provided generous knowl-
edge on the complex interplay between radiotherapy 
and the immune system [10–14]. This research has led 
to the recognition that the therapeutic effects of radia-
tion may depend on antitumor immune responses in 
addition to direct cytotoxic effects [15, 16]. Given the 
combined tumoricidal and immunomodulatory poten-
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hypo-fractionated regimens [17–20], exploring the syner-
gistic combination of immune checkpoint blockade with 
SBRT has gained significant attention [21, 22]. Despite 
encouraging advances in our understanding of the immu-
nogenic effects of RT, more knowledge is still needed to 
define how RT can be maximally exploited as an immu-
nological adjuvant.
Cancer-associated fibroblasts (CAFs) represent a het-
erogeneous group of stromal cells in the TME [23] that 
are both phenotypically and epigenetically different 
from normal fibroblasts [24–27]. Unlike normal tissue-
resident fibroblasts, CAFs are perpetually activated [28] 
and exert their biological effect by modulating the extra-
cellular matrix and by secreting soluble factors such as 
growth factors and cytokines [29]. The presence of CAFs 
in the TME is correlated with increased angiogenesis, 
invasion and metastases, and thus associated with worse 
prognosis in many cancers, including colorectal, pancre-
atic, esophageal cancer and head and neck squamous cell 
carcinoma. Although considerable efforts are currently 
devoted to explore if and how CAFs are contributing to 
therapeutic resistance [25, 30], the plasticity and het-
erogenic nature of CAFs is certainly hampering progres-
sion in the field [23, 31], with specific subsets [30, 32–36] 
reported to mediate either pro-tumorigenic/immunosup-
pressive [30] or anti-tumorigenic/immunogenic effects 
[37, 38].
The sum of inflammatory stimuli, desmoplastic reac-
tions and the highly immunosuppressive milieu brought 
by secretory CAFs to the TME [39, 40], are collectively 
affecting both recruitment and function of innate and 
adaptive immune cells in tumors [41–43]. Thus, although 
CAFs are often disregarded in immunological settings, 
their strong negative influence on anti-tumor responses 
should not be missed out on the journey towards opti-
mized radio-immunotherapy outcomes. In radiotherapy 
settings, the effects of radiation on CAFs vary among dif-
ferent studies, and the potential role of CAFs on tumor 
radio-resistance is still controversial. The scope of this 
review is to gather existing knowledge on effects of radia-
tion on CAFs; to elucidate the influence CAFs may exert 
on radiotherapy outcomes; and to summarize present 
knowledge on the transformed cellular crosstalk between 
CAFs and immune cells after radiation.
Immunoregulatory functions of CAFs
Stromal and immune cells in tumors are engaged in a 
bidirectional crosstalk that involve the release of solu-
ble signal molecules as well as contact-dependent inter-
actions (Fig.  1). Thus, on one hand, pro-inflammatory 
cytokines released by tumor-infiltrating immune cells, 
such as TNF-α and IL-1β, can favor recruitment and acti-
vation of mesenchymal progenitor cells into tumors. In 
turn, tumor-activated fibroblasts, i.e., CAFs, can further 
worsen inflammatory reactions by secreting a myriad 
of chemokines and cytokines that sustain chemotaxis 
and polarization of immune cells to the tumor bed [41, 
42, 44]. Of note, resident and recruited immune cells are 
commonly polarized towards an immunosuppressive 
phenotype within the TME, that supports tumor pro-
gression and therapy resistance. Besides the direct effects 
exerted by CAFs on inflammatory and adaptive immune 
cells, CAFs participate actively in extracellular matrix 
(ECM) deposition, tissue stiffness and tumor angiogen-
esis, thus indirectly affecting migration and function of 
multiple immune cells subsets into the TME [45].
Direct effects
Direct effects of CAFs on innate immunity
The functional interplay between CAFs and tumor-
associated macrophages (TAMs) is an important deter-
minant for tumor progression [46–48]. Stromal cells in 
tumors participate actively in recruitment of TAMs and 
their polarization towards the anti-inflammatory, tumor-
supportive M2-phenotype. It has been shown that CAF-
secreted soluble factors including CXCL12/SDF-1 [49], 
CCL2, IL-6, IL-10, IL-33 [50], granulocyte–macrophage 
colony-stimulating factor (GM-CSF), and chitinase-3 like 
protein 1 Chi3L1 [51, 52] are essential in macrophage 
recruitment and polarization (reviews in [44, 53]). 
Besides, CAFs are able to influence macrophage biology 
and interfere with potential therapeutic approaches to 
block tumor-associated macrophages (TAMs), by pro-
moting ECM remodeling and recruiting myeloid-derived 
suppressor cells (MDSCs) [54]. Furthermore, CAFs can 
also influence neutrophil chemotaxis and polarization 
in the TME [55]. CAF-secreted IL-33 and CXCL12 pro-
mote recruitment of neutrophils to TME, whereas CAF-
derived IL-6 induces neutrophil activation and survival 
through activation of IL-6/STAT3/programmed death-
ligand 1 (PD-L1) signaling pathway. Increased neutrophil 
expression of PD-L1 culminates in impaired T cell medi-
ated immunity. Conversely, neutrophils in tumors can 
mediate transformation of mesenchymal stem cells into 
CAFs by releasing inflammatory cytokines like IL-17, 
IL-23, and TNF-α [56].
Moreover, CAFs have been shown to exert direct 
immunoregulatory activities towards antigen-presenting 
dendritic cells (DCs). CAF-secreted TGF-β, tryptophan 
2,3-dioxygenase (TDO2), IL-6, and thymic stromal lym-
phopoietin (TSLP) have been shown to directly affect 
DC recruitment and differentiation, promoting a tolero-
genic phenotype characterized by lower expression of 
MHC class II molecules and co-stimulatory receptors 
CD40, CD80, and CD86, increased levels of suppres-
sive cytokines and increased regulatory T cell (Treg) 
Page 3 of 13Hellevik et al. J Transl Med          (2021) 19:437  
expansion [57–59]. These CAF-educated DCs pro-
moted tumor infiltration of immunosuppressive Treg 
(CD4 + CD25 + Foxp3 +) cells and decreased production 
of IFN-γ from CD8 + T cells [57]. The interplay between 
CAFs and DCs has also been shown to affect the ability 
of DCs to induce differentiation of T cells into a type-2 
helper T cell (Th2) phenotype in pancreatic cancer, pre-
sumably via CAF-secretion of TSLP [59].
Stromal cells and their progenitors also facilitate 
recruitment of MDSCs, an immature population of bone 
marrow-derived myeloid cells that exert potent immu-
nosuppressive effects. CAF-secreted CXCL12/SDF-1, 
CCL2, IL-6, CXCL1, VEGF, TGF‐β, prostaglandin E2 
(PGE2), and GM-CSF are factors thought to influence 
MDSC recruitment and differentiation [54, 60, 61]. In 
a pancreatic cancer model, CAFs could attract mono-
cytes and further differentiate them into MDSCs via 
IL-6-mediated STAT3 activation [60]. Moreover, a sub-
population of FAP-α expressing CAFs was shown to 
promote tumor growth by secretion of CCL2 and sub-
sequent recruitment of MDSCs in murine models of 
hepatic cancer, liver, and lung squamous cell carcinoma 
[62]. Collectively, the miscellaneous effects of CAFs on 
the different sub-types of inflammatory cells aid in estab-
lishing an immunosuppressive environment in tumors 
and can polarize helper T cell responses toward an 
Fig. 1 CAF‑mediated immunoregulatory functions in the tumor microenvironment. Cancer‑associated fibroblasts (CAFs) participate actively in 
the reciprocal communication with tumor and immune cells in the tumor microenvironment (TME) and are recognized contributors to immune 
escape by affecting recruitment and function of different innate and adaptive immune cells. Effects from CAFs on immune cells can be exerted 
directly via release of potent immune regulators and exosomes and/or expression of regulatory receptors on the cell surface, as well as indirectly 
by regulation of extracellular matrix (ECM), tissue stiffness, angiogenesis and hypoxia. Red arrows represent negative regulation, and blue arrows 
represent positive regulation. bFGF basic fibroblast growth factor; CD73 cluster‑of‑differentiation‑73; CCL2 chemokine (C–C motif ) ligand 2; CHI3L1 
chitinase‑3 like protein 1; coll collagen; CTL cytotoxic T lymphocyte; CXCL1 chemokine (C–X–C motif ) ligand 1; DC dendritic cell; ECM extracellular 
matrix; GM-CSF granulocyte–macrophage colony‑stimulating factor; HA hyaluronan; IDO Indoleamine‑2,3‑dioxygenase; IL interleukin; LOX lysyl 
oxidase; MDSCs myeloid‑derived suppressor cells; MMP matrix metalloproteinases; MØ macrophages; NK cell natural killer cell; PD-L1 programmed 
death ligand‑1; PGE2 prostaglandin E2; SDF-1 stromal‑derived factor‑1; TDO2 tryptophan 2,3‑dioxygenase; TGFβ transforming growth factor beta; T 
reg regulatory T cells; TSLP thymic stromal lymphopoietin; VEGF vascular endothelial growth factor. Schematic created by BioRender
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immunosuppressive Th2 profile, which further support 
tumor progression (Fig. 1).
Direct effects of CAFs on effector immune cells
CAF-mediated immunosuppression also involves inhi-
bition of multiple effectors of anticancer immune 
responses. Natural killer (NK) cells play an important 
role in tumor immunity acting as innate effector cells 
[63]. CAF-secreted soluble factors including TGF-β, 
PGE2, Indoleamine-2,3-dioxygenase (IDO), matrix-
metalloproteinases (MMPs), and surface expression of 
checkpoint ligands such as the poliovirus receptor (PVR/
CD155) or PD-L1 may modulate NK cells immune phe-
notype. Several in  vitro studies have document CAF-
induced changes in the expression of activating receptors 
(NKp30, NKG2D, NKp44, NKp30, and DNAM-1), inhibi-
tory receptors (NKG2A, KIR2DL1, and KIR3DL1), pro-
duction of cytolytic granules (perforin and granzyme B) 
and cytokine release by NK cells [64–68].
Along similar lines, CAFs are inhibiting the activity 
of CD8 + cytotoxic T lymphocytes (CTL) by different 
means: (A) expressing immune checkpoint molecules 
including PD-L1 and PD-L2 and FAS ligand [69]; (B) 
secreting soluble mediators, e.g., CXCL12/SDF-1, IL-10, 
PGE2, nitric oxide and TGF-β [70], and (C) inducing 
metabolic rewiring through high consumption of glu-
cose, arginine and tryptophan (all of which are required 
for optimal expansion of CTLs), in parallel to an elevated 
expression of IDO-1 [71], arginase 1 [72] and lactate 
[73]. In addition, CD4 + , CD25high, Foxp3 + Tregs can 
be recruited into tumors and expanded by CAFs either 
by secretion of IL-6, PGE2, and CXCL12/SDF-1 or by 
expressing OX40L, PD-L2, and JAM2 [33, 71]. MHC-
II expressing fibroblasts have recently been described 
to increase Treg numbers in pancreatic cancer, through 
PGE2 expression and down-regulation of co-stimulatory 
ligands necessary to activate immune effector T cells 
with potential to mediate antitumor immunity [74]. In 
the TME, the presence of CAFs and their secretion of 
chemokines and cytokines such as CCL2, CCL5, CCL17, 
IL-1, IL-6, IL-13, and IL-26 can favor a tumor-promot-
ing Th2 and Th17 immune response, at the expense of 
tumor-protective Th1 responses [75, 76].
Indirect effects
CAF‑mediated ECM remodeling and fibrotic reactions
Fibroblasts are engaged in connective tissue homeo-
stasis and participate in both ECM deposition and 
turnover. Hence, in addition to direct cell–cell commu-
nications, CAFs may contribute to immune cell modu-
lation indirectly by affecting interstitial pressure and 
tissue stiffness. In cancer settings, CAFs are main suppli-
ers of fibrous collagens, fibronectin, elastin, laminin and 
ECM‐remodeling enzymes like collagen crosslinking lysyl 
oxidase (LOX), MMPs and tissue-inhibitors-of-metallo-
proteinases (TIMPs). Altogether, the wide collection of 
CAF-secreted molecules is affecting tissue stiffness [77] 
and represents a physical barrier for tumor-infiltration of 
blood, immune cells, drugs and  (O2) molecules [24, 78], 
(review in [79]). In human pancreatic ductal adenocarci-
noma (PDAC) [80] and lung cancers [81], high levels of 
fibrosis have been correlated with poor  CD8+ CTL infil-
tration and motility [81], (review in [82]). Conversely, in 
a mouse model of spontaneous PDAC, deletion of colla-
gen type-I from αSMA + CAFs induced elevated CXCL5 
expression from tumor cells, immunosuppression and 
concomitant recruitment of MDSCs [83]. Based on a 
similar hypothesis, focal adhesion kinase (FAK) activity 
was proposed as a druggable CAF-target [84], with inhi-
bition reducing fibrosis and rendering pancreatic cancers 
responsive to checkpoint immunotherapy [85]. However, 
similarly to collagen-I depletion [86], resistance to FAK 
inhibition is apparently linked to stromal depletion [87].
CAF‑mediated effects on tumor vasculature and hypoxia
Stromal cells in tumors are also potent regulators of 
angiogenesis and tumor perfusion. Different mecha-
nisms have been described for these effects including 
(1) secretion of pro-angiogenic factors, like VEGF, bFGF 
and SDF-1 [49, 88]; (2) surface expression of galectin-1 
and podoplanin that upregulate VEGF in cancer cells 
[89, 90]; (3) activation of TGF-β signaling that triggers 
angiogenesis by upregulating VEGF expression on CAFs 
[91]; and (4) ECM remodeling [92]. Hence, indirectly, 
CAFs participate in the generation of hypoxic zones that 
in turn contribute to an immunosuppressive TME [26]. 
Hypoxia reportedly impair antitumor immune responses 
by activation of hypoxia-inducible factor-1α (HIF-1α) 
[93], which in turn, upregulates PD-L1 expression by 
MDSCs, macrophages, DCs, and tumor cells, thereby 
promoting T cell inactivation through the PD-1/PD-L1 
axis [94, 95]. Hypoxia also triggers CD39 and CD73 
ecto-nucleotidases, thereby generating extracellular 
(immunosuppressive) adenosine [96, 97]. Taken together, 
CAFs may indirectly interfere negatively with anti-tumor 
immunity by contributing to increased tissue stiffness 
and thereby promoting an immunosuppressive hypoxic 
microenvironment.
Role of CAFs in radiotherapy
Direct effects of ionizing radiation on CAF phenotype 
and functions
CAFs in solid tumors are located intermingling and in 
close proximity to cancer cells, very frequently occupy-
ing areas corresponding to connective tissue bundles 
surrounding tumor cell nests [78]. As main elements of 
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the supportive stromal tissue in tumors, CAFs receive 
the same prescribed radiation dose as tumor cells dur-
ing radiotherapy. Studies investigating cytotoxic effects 
of IR have revealed the intrinsic radio-resistant nature 
of fibroblasts [98–100]. Numerous in  vitro observa-
tions have confirmed that following radiation expo-
sure, CAFs evade cell death but acquire a senescent 
phenotype accompanied by impaired proliferation and 
migration rates (Fig.  2). In the study by Tommelein 
et al. [101] irradiated colorectal-CAFs did not undergo 
cell detachment or death but demonstrated substantial 
DNA damage and growth delay that was maintained 
in long-term cultures. Non-small-cell lung carcinoma 
(NSCLC)-CAFs have demonstrated dose-dependent 
DNA damage responses following single-dose radiation 
(2, 6, 12 or 18 Gy), and senescence induction was pro-
portional to the radiation dose [98]. In the same study, 
radiation appeared to impede CAF mobility by stabiliz-
ing focal contacts through increased surface expression 
of integrins [98].
Genome-wide studies conducted to map the over-
all changes in gene-expression undergone by irradiated 
fibroblasts have revealed that some critical pathways 
become persistently altered by radiation, including cell-
cycle and proliferation, DNA-damage responses, pro-
grammed cell death, p53/p21 response genes, reactive 
oxygen species (ROS) scavenging, ECM remodeling and 
growth factors receptor signaling [102, 103].
Importantly, following radiation, CAFs maintain 
elevated levels of cytokine secretion but display a par-
tially altered secretory phenotype (Fig.  2). Colorec-
tal-CAFs have demonstrated increased secretion of 
numerous proteins following a fractionated low-dose 
regimen (10 × 1.8  Gy), including angiopoietin-like 2 
(ANGPTL2) and VEGF involved in angiogenesis, along 
with increased levels of Dickkopf WNT signaling path-
way inhibitor-1 (Dkk-1), secreted frizzled-like protein-4 
(sFRP-4) and LDL receptor-related protein-6 (LRP-6) 
[101]. Others have found that NSCLC-CAFs respond 
to radiation by increased secretion of basic fibroblast 
growth factor (bFGF), growth arrest-specific protein 6 
(GAS-6) and macrophage migratory inhibitory factor 
(MIF), but decreased CXCL12/SDF-1, connective tis-
sue growth factor (CTGF) and IL-6 [104]. The secretory 
phenotype of irradiated CAFs seem to differ across dif-
ferent studies, an issue that may depend on experimental 
features such as tumor type, cell source or radiation regi-
men. In the context of cellular communication, a recent 
in vitro study has demonstrated that the secretion rates 
and the protein cargo of extracellular vesicles released by 
NSCLC-CAFs remains unchanged following single high 
dose or hypo-fractionated radiation exposure [105].
Activation of normal fibroblasts by radiation
A frequent misconception in the field of CAFs and radia-
tion is to generalize observations attained with CAFs and 
Fig. 2 Side‑by‑side comparison of radiation effects exerted on normal fibroblasts and cancer‑associated fibroblasts (CAFs). Compared to 
their normal counterparts, CAFs exhibit higher proliferation and migration rates, and actively participate in sustaining a pro‑inflammatory and 
immunosuppressive tumor microenvironment. Exposure to ionizing radiation (IR) in vitro have been shown to activate normal tissue resident 
fibroblasts, rendering them more pro‑tumorigenic, whereas the effects of radiation on CAF tumorigenic functions remain controversial. NFs normal 
fibroblasts; iNFs irradiated normal fibroblasts; iCAFs irradiated CAFs
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with normal (quiescent) fibroblasts. This is a highly rel-
evant issue that deserves careful consideration. To under-
stand the contribution of CAFs to therapeutic outcomes 
post-RT, the activated status of the cell pre-treatment 
should be considered (Fig.  2). Additionally, in contem-
porary radiotherapy settings, only cells residing within 
the delineated tumor volume or its periphery (CAFs) are 
exposed to the full prescribed radiation dose, whereas 
healthy tissue located outside the irradiated field (normal 
fibroblasts) may receive only residual radiation doses.
Because of the above-mentioned inaccuracies, there 
is a generalized view that promulgates an enhanced 
pro-malignant nature of irradiated fibroblasts/CAFs, 
irrespective of their origin. Indeed, most of the existing 
knowledge in this topic emerges from studies conducted 
with normal tissue fibroblasts or fibroblast cell-lines. The 
pro-malignant phenotype acquired by normal fibroblasts 
turning senescent post-RT has been thoroughly docu-
mented [100, 106]. Also, numerous in vitro studies have 
demonstrated increased invasiveness, proliferation rates 
and radio-resistance of tumor cells exposed to irradiated 
versus non-irradiated normal fibroblasts [107–109]. To 
these studies we must add observations on tumor bed 
effects when both tumorigenic and non-tumorigenic 
epithelial cells are transplanted into irradiated normal 
tissue [110, 111]. In contrast to (quiescent) normal tis-
sue fibroblasts, tumor-reactive fibroblasts or CAFs (in 
non-irradiated conditions) actively produce numerous 
tumor-promoting molecules such as MMPs, inflamma-
tory cytokines, pro-angiogenic factors and miscellaneous 
tumor-promoting growth factors [24–26] (Fig. 2). In the 
next chapter, we discuss radiation studies performed spe-
cifically with CAFs.
Effects of radiotherapy on CAF pro‑tumorigenic functions
In an effort to understand the role of CAFs on tumor 
radio-resistance, different groups have explored the 
direct radioprotective effects exerted by (non-irradiated) 
CAFs on cancer cells. Some in  vitro studies have dem-
onstrated radioprotective effects of CAF-conditioned 
medium on survival and colony-forming abilities of pan-
creatic cancer cells [112] and HeLa cells [113]. Zhang 
et  al. [114] suggested that CAF-derived CXCL1 and 
the subsequent reduction in ROS scavenging enzyme 
superoxide dismutase-1 in cancer cells is responsible for 
induction of a radioresistant phenotype in esophageal 
squamous cancer cells (ESCC) [114]. In models of mel-
anoma and lung cancer, elevated expression of insulin 
growth factor 1 (IGF-1) and chemokine CXCL12/SDF-1 
by CAFs (non-irradiated) have been shown to be respon-
sible for radioprotective effects on cancer cells [115]. 
Whereas in a pancreatic cancer model, authors suggest 
that increased expression of TFG-β and possibly other 
soluble factors from pancreatic stellate cells (PSCs) medi-
ate EMT changes and acquisition of a radioresistant phe-
notype [116].
In addition to the general radioprotective functions 
assigned to CAFs, some studies claim that radiation 
exposure is amplifying the intrinsic radioprotective and 
pro-malignant effects exerted by CAFs. Upon co-cultur-
ing with irradiated CAFs, cells from ESCC were found 
to scatter in a dose-dependent manner, thus reflecting 
increased migratory behavior [117]. The effects were 
attributed to increased expression of hepatoma-derived 
growth factor (HDGF) by irradiated CAFs compared to 
non-irradiated controls. In another in vitro study, CAFs 
irradiated with single doses of 5 or 10  Gy triggered 
increased invasiveness of pancreatic cancer cells com-
pared to non-irradiated CAFs [118]. Authors observed 
increased phosphorylation of HGF receptor in CAF-
educated tumor cells, however levels of HGF in irradi-
ated CAF-conditioned medium were unchanged [118]. 
Similarly, in a study by Li et  al. [119] irradiated CAFs 
provoked enhanced invasive capacity of pancreatic can-
cer cells in co-cultures. Irradiated CAFs were found to 
excrete increased levels of CXCL12/SDF-1, ultimately 
promoting cancer cell migration, invasion and epithe-
lial-mesenchymal transition, aiding in the overall tumor 
progression [119]. Again, in a pancreatic cancer model, 
Mantoni et  al. [120] demonstrated that PSCs promote 
radioprotection and stimulate proliferation of pancre-
atic cancer cells in direct co-cultures and after co-injec-
tions in  vivo. In that study, interfering with β1-integrin 
signaling abolished the radioprotective effects [120]. 
Tommelein et  al. [101]found increased IGF signaling in 
irradiated colorectal-CAFs, and both IGF-1 and IGF-
binding proteins (IGFBP2) levels were almost three-fold 
higher in supernatants from irradiated versus non-irradi-
ated CAFs [101].
In contrast to the generalized view postulating a radi-
ation-enhanced activation of CAFs, some studies docu-
ment a loss of CAF pro-tumorigenic functions after 
irradiation. In a study by Hellevik et  al. [99], the tumor 
enhancing effects exerted by CAFs, when co-injected 
with A549 lung tumor cells in xenografts, was lost when 
CAFs were irradiated pre-implantation [99]. Recently, 
Arshad et al. [121], reported that murine lung-CAFs did 
not modulate the intrinsic radio-sensitivity of cancer 
cells, and reduced TGF-β and MMPs secretion in co-
culture supernatants was observed post-RT (1 × 10  Gy) 
[121]. In a recent study by Steer et  al. [122], the radio-
protective and long-term survival effects of CAFs over 
cancer cells were studied in 2D and 3D in vitro systems, 
using different sets of fibroblasts and tumor cell-lines. 
Results were inconsistent among different fibroblast-
tumor cell combinations [122]. Similar observations were 
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obtained after co-implantation of cells in xenografts. 
Authors concluded that the impact of fibroblasts on can-
cer cell behavior and radiation sensitivity largely depend 
on the respective cell type combination and that effects 
cannot be generalized. In clinical settings, Maaren et al. 
[123] reported that women diagnosed with early-stage 
breast cancer undergoing breast-conserving surgery plus 
radiotherapy displayed significantly improved 10  years 
overall and relative survival compared to women receiv-
ing mastectomy only [123]. This suggests that residual 
irradiated stroma is aiding in the long-term anti-tumor 
immunity. As a major constituent of the tumor stroma 
[24], CAFs and/or fibroblasts are likely to be involved 
in the long-term positive anti-tumor effects reported by 
Maaren et al.
Immunoregulatory features of irradiated CAFs
While the multifactorial immunoregulatory functions 
of CAFs have been widely studied and thoroughly docu-
mented [42, 44], CAF-mediated immunoregulation in the 
radiation context has been poorly investigated. As indi-
cated earlier, CAFs are recognized as highly radioresist-
ant, and as such, even at clinically high radiation doses, 
CAFs avoid cell death and instead enter into a perma-
nent senescent state. Consequently, CAFs are not par-
ticipating in anti-tumor adjuvanticity with the release 
of immunogenic cell death signals following RT [124]. 
Moreover, cultured NSCLC-CAFs do not switch on IFN 
type I responses after single-high dose (1 × 18  Gy) or 
fractionated (3 × 6  Gy) radiation [125]. However, radia-
tion is inducing phenotypic changes in CAFs that could 
influence post-RT immunoregulation. Hence, IR-induced 
senescent NSCLC-CAFs display enhanced expression 
of several cell surface inhibitory ligands such as CD155, 
HLA-E, CD73, and Fas receptor whereas expression 
of other immune regulatory ligands such as PD-L1 and 
CD112 seem unchanged (Fig.  3) [68]. The observed 
phenotypic changes could affect NK cell- and T cell-
mediated tumor immune attack, although differences 
in effector cell immune functions were not observed in 
(irradiated) CAFs/NK cells co-culture settings. Notably, 
radiation has been shown to trigger surface expression of 
Fas death receptor in cultured CAFs, however, this cel-
lular response appeared insufficient to guide immune-
mediated elimination of radiation-induced senescent 
CAFs [68].
Several studies have documented RT-mediated 
changes in CAF-expression of soluble immunomodu-
lators, which could exert direct regulation on immune 
cell chemotaxis and/or functions. CAFs from ESCC 
have demonstrated enhanced expression of the chem-
oattractant CXCL1 post-IR [114]. Increased expression 
of CXCL12/SDF-1 by CAFs following irradiation has 
been also reported in pancreatic cancer [119], mela-
noma and lung cancers [115]. In the latter two studies, 
authors elaborate on CAF/tumor cell effects without 
exploring immuno-modulation, however, CXCL12/
SDF-1 may exert measurable impact on immune cell 
recruitment and/or polarization and thus, CXCL12/
SDF-1-mediated immunomodulation could potentially 
take place. Studies using normal fibroblasts or fibro-
blast cell-lines in culture have reported elevated TGF-β 
[107], IL-6 and IL-8 expression [106] following irradia-
tion of cells with 1 × 12 Gy and 1 × 10 Gy, respectively. 
In a study by Hellevik et  al. [104], a comprehensive 
analysis of the entire secretome of cultured NSCLC-
CAFs irradiated with 1 × 18  Gy was performed using 
proteomics and multiplex protein assays. Results from 
that study demonstrated reduced SDF-1 expression and 
unaffected expression of miscellaneous immunomodu-
lators including IL-6, IL-8, Il-1β, TNFα and TGF-β. 
Inconsistencies in outcomes across different studies 
could be related to variations in experimental param-
eters such as tumor types, cell sources, radiation doses, 
culturing characteristics and timing for sample collec-
tion post-IR.
As described earlier, CAF may influence immune 
cell infiltration and functions indirectly through ECM 
deposition and matrix remodeling. The fibroprolif-
erative reactions frequently observed post-RT is the 
consequence of perpetuated wound healing responses 
[126]. Following radiation exposure, the subsequent 
upregulated secretion of TGF-β [127, 128] promotes 
activation of quiescent fibroblasts into myofibroblasts 
[129]. Nevertheless, participation of irradiated CAFs 
towards RT-induced profibrotic responses has not been 
thoroughly demonstrated hitherto. In an oral squamous 
cell carcinoma model, enhanced TGF-β expression was 
observed from different fibroblast cell-lines exposed to 
(1 × 12 Gy) [107]. However, unchanged TGF-β expres-
sion has been reported from senescent NSCLC-CAFs 
exposed to single-high (1 × 18  Gy) radiation dose [51, 
124]. Papadopoulou et  al. [100] reported enhanced 
expression of MMPs as partially responsible for the 
pro-tumorigenic effects exerted by radiation-induced 
senescent lung fibroblast. In contrast, Hellevik et  al. 
[98] reported down-regulated MMP-1 from irradi-
ated lung-CAFs, and also Arshad et al. [121] observed 
reduced secretion of TGF-β and MMP after simul-
taneous irradiation of fibroblasts and cancer cells in 
co-cultures (1 × 10  Gy) [121]. Accumulated evidences 
suggest that stress-induced senescent fibroblasts dis-
play a rather catabolic phenotype, characterized by 
reduced expression of structural ECM proteins and ele-
vated expression of proteolytic enzymes [130].
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Interplay between CAFs and immune cells after radiation
The immunoregulatory functions exerted by CAFs have 
been extensively documented, however, as described 
in this review, radiation exerts substantial phenotypic 
changes in CAFs, so the question still remains: are the 
inherent immunomodulatory functions of CAFs changed 
after radiation exposure, and if so in which direction? 
Very scant knowledge exists in this respect. Four separate 
studies have recently been exploring how IR is affecting 
CAF-mediated immunoregulatory functions over differ-
ent adaptive and innate immune cells in vitro (Fig. 3).
A first study, performed with white blood cells iso-
lated from peripheral blood of randomly selected healthy 
donors, compared effects from control and irradiated 
Fig. 3 Cancer‑associated fibroblasts (CAFs) maintain their immunosuppressive phenotype following exposure to ionizing radiation (IR). Radiation 
treatment by IR is able to induce weighty changes in the phenotype of CAFs, however recent studies have demonstrated that CAFs retain their 
immunosuppressive functions over different innate and adaptive immune cells after radiation treatment. The release of key immunoregulators 
remain constant in radiation‑induced senescent CAFs. In contrast to what has been observed with tumor cells, CAFs do not undergo immunogenic 
cell death (ICD) and do not activate interferon type 1 (IFN‑1) responses following radiation, while expression of some inhibitory surface receptors is 
enhanced. CCL2 chemokine (C–C motif ) ligand 2; CHI3L1 chitinase‑3 like protein 1; CD73 cluster‑of‑differentiation‑73; CTL cytotoxic T lymphocytes; 
DC dendritic cells; FasL Fas (or CD95) ligand; GM-CSF granulocyte–macrophage colony‑stimulating factor; ICD immunogenic cell death; IDO 
Indoleamine‑2,3‑dioxygenase; IFN-1 type I interferon; IL-6 interleukin‑6; Mø Macrophages; M2-MØs (anti‑inflammatory) type‑2 macrophages; NK cell 
natural killer cell; PD-L1 programmed death ligand‑1; PGE2 prostaglandin E2; TDO2 tryptophan 2,3‑dioxygenase; tDC tolerogenic dendritic cell; TSLP 
thymic stromal lymphopoietin; TGFb transforming growth factor beta. Schematic created by BioRender
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CAFs over lymphocytes [124]. Regulation of lymphocytic 
activation (including both CD4 + and CD8 + T cells) 
was examined in proliferation, migration and cytokine 
release assays. In all functional assays, CAF-conditioned 
medium induced powerful immunosuppressive effects on 
activated T cells, and this effect was sustained by senes-
cent CAFs after single-dose radiation (2  Gy or 18  Gy). 
Importantly, relevant immunosuppressive molecules 
such as PGE2, IL-6, IL-10, or TGF-β were measured in 
CAF-conditioned medium, but their secreted levels were 
unchanged post-irradiation [125].
A second study investigated how IR modulates CAF-
mediated regulatory effects over exogenously polarized 
monocyte-derived macrophages [51]. NSCLC-CAFs 
were shown to inhibit pro-inflammatory features of 
M1-macrophages, including reduced expression of 
M1-surface markers, nitric oxide production, pro-
inflammatory cytokines and migration rates. Radiation 
delivered to CAFs as single-high dose (1 × 18  Gy) or in 
fractioned regimens (3 × 6  Gy) did not modify their 
immunoregulatory features over macrophages in  vitro. 
Of note, protein expression analyses in CAF supernatants 
showed that irradiated and non-irradiated CAFs secrete 
similar quantities of immunoregulators such as GM-CSF, 
monocyte chemoattractant protein-1 (MCP-1), VEGF-A, 
IL-4, -6, -8, -10 and Chi3L1 [51].
In a third study, CAF-mediated immunoregulatory 
effects on NK cells were compared with or without radia-
tion [68]. Results revealed that cytokine-activated NK 
cells in direct contact with NSCLC-CAFs display a phe-
notype characteristic of tolerogenic NK cells, as indicated 
by reduced cytotoxic capacity, reduced degranulation, 
reduced expression of activating receptors (NKG2D, 
NKp46, DNAM-1) but enhanced surface expression of 
inhibitory receptors like NKG2A. Notably, radiation 
exposure to CAFs did neither improve nor worsen the 
overall CAF-induced immunosuppression on NK cells. In 
line with observations from functional assays, the release 
of relevant soluble immunoregulators such as PGE2, 
TGF-β, or IDO by control and irradiated CAFs remained 
unchanged. Interestingly, authors demonstrated 
enhanced surface expression of Fas (death receptor) 
and HLA-E in irradiated CAFs, however, these cellular 
responses turned out insufficient to initiate immune rec-
ognition and elimination by NK cells [68].
In a fourth study, effects of IR towards CAF-mediated 
regulation of DCs was explored [125]. Results showed 
that CAFs, both by conditioned medium and in co-cul-
tures, interfere with monocyte differentiation into DCs 
and induce a tolerogenic phenotype on mature DCs. This 
was evidenced by decreased expression of classic acti-
vation markers (CD80, CD86, CD40 and HLA-DR) and 
reduced functional properties (migration, antigen uptake, 
and CD4 + T cell priming). Interestingly, IR applied in 
fractionated medium-doses (3 × 6  Gy) abrogated some 
of the CAF-mediated effects on DCs, however CAF-
derived TSLP and tryptophan 2,3-dioxygenase (TDO2) 
levels were unchanged, suggesting that radiation-induced 
effects were not related to modulation of previously high-
lighted soluble mediators. Together, this study suggests 
that certain radiation regimens may modify favorably the 
inherent immunosuppressive functions of CAFs towards 
DCs [125]. The rationale behind these observations is still 
unknown, and the results presented in this study should 
also be confirmed in more complex in vivo models.
Concluding remarks
Besides triggering direct cytotoxic effects on malignant 
cells, clinical radiotherapy is causing profound cellular 
and molecular reconfigurations in the TME that ulti-
mately may impact tumor immune recognition [6, 7]. 
Numerous in vitro and in vivo studies have documented 
the profound changes provoked by radiation in tumor 
constituents such as the vasculature, desmoplasia, mes-
enchymal cells, inflammatory cells and bone marrow-
derived progenitor cells [6, 7]. Effects of radiotherapy on 
CAFs vary among different studies, and the potential role 
of CAFs on tumor radioresistance is still controversial. 
Discrepancies between studies may arise due to differ-
ent experimental parameters including tumor model, cell 
sources, in  vitro culture conditions, radiation regimens 
and time post-treatment for data collection. In this con-
text, generalization of results obtained with normal tis-
sue fibroblasts, fibroblast cell-lines and CAFs isolated 
from tumor specimens is a frequent and non-redundant 
matter. To understand the contribution of CAFs to thera-
peutic outcomes post-RT, the activated status of the cells 
pre-treatment should always be considered. In addition, a 
considerable number of studies have explored the radio-
protective effects of CAFs or their conditioned medium 
in non-irradiated conditions. Considering that CAFs are 
building blocks of the tumor mass, and therefore receive 
the prescribed radiation dose in full, studies exploring 
CAF-mediated radioprotection should consider doing it 
with irradiated cells.
We are gradually uncovering the important effects that 
radiotherapy exert on fibroblasts, and start to decipher 
the complex interplay between different TME elements 
during and after RT. However, there are clear limita-
tions in the studies published in this field hitherto. Most 
of the presented studies have used single radiation doses 
or regimens and have collected data at specific time 
points, normally few hours/days post-radiation. These 
approaches overlook potential differences related to dif-
ferent RT-regimens, and disregard potential long-term 
effects of RT on CAFs. Besides, studies performed on 
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in  vivo models commonly use co-injections of human 
tumor cells and fibroblasts/CAFs in subcutaneous pock-
ets or orthotopically in immunodeficient mice. However, 
in such models, human fibroblasts are rapidly replaced by 
host fibroblasts [99], and immunological effects are not 
taken into account. Transgenic mouse models, where 
endogenous CAFs can be regulated, could represent 
attractive models to explore CAF-mediated influence on 
RT-outcomes.
There exist a plethora of studies demonstrating that 
mesenchymal cells in tumors can exert powerful immu-
noregulation, directly affecting the polarization of 
immune cells within the TME and influencing their spa-
tial localization and functionality. However, CAFs repre-
sent a highly diverse population of cells, thus while the 
immunosuppressive effects from CAFs are overrepre-
sented in the literature, some studies have demonstrated 
specific immune-mediated tumoricidal effects orches-
trated by specific CAF sub-populations [37, 38]. Future 
studies on the immunoregulatory roles of CAFs should 
embrace the heterotypic view of CAFs, identifying CAF 
subtypes by specific set of markers, and assigning effects 
to specific CAF subclasses.
In the context of radiotherapy concretely, CAF-medi-
ated immunoregulation has been poorly investigated. 
Numerous in vitro studies have shown enhanced expres-
sion of immunoregulatory cytokines and growth factors 
by irradiated fibroblasts; however, the scenario is differ-
ent when the cells in focus are CAFs instead of quies-
cent fibroblasts or cell lines. Another relevant finding is 
the upregulation of checkpoint ligands and other inhibi-
tory receptors on irradiated CAFs, a circumstance that 
could play a role in contact-dependent effector immune 
cells regulation. Furthermore, recent studies based on 
(irradiated) CAF/immune cell co-cultures have shown 
comparable immunoregulatory effects from irradiated 
and control CAFs over different types of immune cells, 
accompanied by similar expression of soluble immu-
nomodulators. Collectively, these in vitro studies propose 
equivalent immunoregulatory abilities by irradiated and 
non-irradiated CAFs. Considering CAFs as one of the 
most notorious immunosuppressive elements in the TME 
and that radiation does not revert or may even enhance 
CAF-mediated immunosuppressive functions, strategies 
to specifically target CAF subtypes or CAF-derived fac-
tors should be considered to gain the full potential of RT 
as an immune adjuvant. In recent years, a wide range of 
CAF-targeting strategies have been tested in preclinical 
and clinical settings [25]. The approaches are very diverse 
and comprise agents targeting ECM components (e.g., 
PEGPH20/hyaluronidase and FG-309 mAb/anti-CTGF), 
CAF-specific contenders (anti-FAP antibodies, FAP 
vaccines or CAR T cells), pathway-specific inhibitors 
(TGFBR inhibitors, CXCR4 inhibitors or NF-kB inhibi-
tors) and drugs that reprogram CAFs to a quiescent 
state (e.g., calcipotriol, tranilast). Recent advances on 
CAF molecular and functional heterogeneity open new 
avenues for cancer treatment. Novel strategies are now 
designed to target CAF-secreted tumor promoting or 
immunosuppressive molecules (IL-6, TGFb, etc.…) or 
inhibiting subtype specific signaling that would ablate a 
particular CAF population. In summary, recent obser-
vations from pre-clinical models suggest that targeting 
CAF could increase immunotherapy efficacy. However, 
it remains unclear which features of the heterogene-
ous CAF phenotype are more important to their role in 
immune evasion in human tumors.
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